

ANCON Medical observes Bowel Cancer Awareness Month, encouraging screening

April is Bowel Cancer Awareness Month (BCAM), supporting fundraising and raising awareness of the mission of Bowel Cancer UK.

CANTERBURY, KENT, UNITED KINGDOM, March 29, 2018 /EINPresswire.com/ -- April is Bowel Cancer Awareness Month (BCAM), supporting fundraising and raising awareness of the mission of Bowel Cancer UK to ensure that by 2050, no-one will die of the disease.

The sooner bowel cancer is diagnosed, the easier it is to treat, but currently, no available screening test is 100 percent accurate. This is why early detection of highly accurate, non-invasive devices like ANCON Medical's NBT can be crucial in treatment.



Human Bowel

Bowel or colorectal cancer is the UK's second biggest cancer killer, however, it shouldn't be because it is treatable and curable especially if diagnosed early. Nearly everyone diagnosed at the earliest stage will survive bowel cancer, but this drops significantly as the disease develops.

“

Shining a light on these sometimes overlooked diseases not only creates awareness of these conditions, it also reminds people of the importance of getting screened”

Wesley Baker - CEO of Ancon Medical

Endoscopy tests, such as a colonoscopy or flexible sigmoidoscopy, are currently the key diagnostic tests for bowel cancer, but the invasive nature of these tests can deter people coming forward.

That's why [ANCON Medical Inc.](#) is helping to recognize BCAM in April, encouraging awareness of the NBT non-invasive screening device.

“Shining a light on these sometimes overlooked diseases not only creates awareness of these conditions, it also reminds people of the importance of getting screened,” said ANCON Medical CEO [Wesley Baker](#). “Like most diseases, an early

diagnosis can mean early treatment, which is especially important in the case of bowel cancer.”

Bowel cancer is precisely the kind of disease where advanced disease screening technology can be life-saving. Non-invasive, simple to use, and affordable, ANCON's Nanoparticle Biomarker Tagging

(NBT) technology can detect the presence of disease by measuring exhaled breath for signs of the disease.

The technology works by detecting in exhaled breath specific “biomarkers,” which are DNA-protein controlled volatile organic compound (VOC) metabolites specific to diseases. Researchers have discovered biomarkers for more than 400 diseases, with Bowel and other cancers among those.

By programming an NBT device to hunt for these specific biomarkers, the disease can be diagnosed early.

“Being programmable makes an ANCON’s NBT device quite versatile. It can be used to screen for diseases like cancer and later be reprogrammed to test for a range of other diseases when needed,” Baker, a member of the Royal Society of Medicine said. “Lung Cancer, Influenza, Cervical Cancer, the Ebola virus, Tuberculosis and COPD (chronic obstructive pulmonary disease) are just some of the diseases where known biomarkers have been discovered.”

For more information on Bowel Cancer symptoms and what to do, visit <https://www.bowelcanceruk.org.uk/>.

Joanna Stephens
Ancon Technologies & Ancon Medical
+44 1227 811705
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.